Drug info - Needed: MAO inhibitors currently in medical use

[Paracelsus]

I need information on the status of various (pharmaceutical) MAO inhibitors. I need to know which ones are approved and currently in medical use (it doesn't matter in what country) and which ones are not. Please share if you know anything. Please do not add MAO inhibitors that (as far as you know) were never approved.

Currently in use:
Isocarboxiazid (Marplan) - available in the US
Phenelzine (Nardil) - available in US
Tranylcypromine (Parnate) - available in the US
Moclobemide (Aurorix)- I know it is available, but I don't know where (it's not approved in the US). Does anyone know?
Selegiline (Eldepryl, Selegos, etc) - available in many places
Rasagiline (Azilect) - FDA approved

Possibly in use (were used at least in human trials but not sure on anything else):
Toloxatone (Humoryl) - was approved in France once. I don't know if it's still used.
Pirlindole AKA pyrazidol - I've read some things, not sure yet.
Lazabemide
Befloxatone - was in trial phase some time ago, not sure if approved.
Clorgyline?
Pargyline?

Not in use anymore (but formerly used):
Brofaromine - was approved & used (US), but the manufacturing company withdrew it for some reason.
AMT (Indopan) - once used (Russia), not used anymore (schedule I in US)
AET (Monase) - once used, not used anymore (schedule I in US)
Nialamide
Iproniazid

[Jatelka]

Available/Licensed in the UK (although rarely used):

Phenelzine
Isocarboxazid
Tranylcypromine
Moclobomide (Reversible MAO A inhibitor, sometimes termed a "RIMA")

MAO B inhibitors used in Parkinsons: Selegeline, Rasagiline

Procarbazine is an oral chemotherapy agent used in Hodgkin's Lymphoma. It is considered a "mild" MAOI and dietary restriction is not considered necessary, although a disulfiram-type reaction can occur if taken with alcohol.

[Zaprenz]

Indantadol [although not approved yet quite interesting & may be approved in future]

CHF 3381 is an NMDA antagonist and monoamine oxidase inhibitor under development with Chiesi for the treatment of neuropathic pain. Preclinical studies show that the agent acts as a reversible and competitive inhibitor of human monoamine oxidases A and B. At the 1st Annual BioPartnering North America (BPN-2003) it was stated that CHF 3381 is being evaluated for the treatment of neuropathic pain. Preliminary data also suggested that CHF 3381 may have neuroprotective activity. In June 2003, Chiesi announced the completion of a phase I trial in France, and is proceeding with a proof-of-concept study in Denmark. CHF 3381 is covered by European patent application EP 951465 (expires on 15 July 2017), and US patent No. 6,114,391 (issued on 5 September 2000). Other patents are granted or pending in 20 countries. Chiesi also has rights to the European patent application for use of glycinamide derivatives (including CHF 3381) in the treatment of chronic pain.PMID: 14725488

Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain.
Indantadol is an oral and nonselective monoamine oxidase inhibitor and NMDA antagonist that is being developed by Vernalis plc, under license from Chiesi Farmaceutici SpA, for the potential treatment of neuropathic pain. In preclinical studies, indantadol exhibited neuroprotective effects after kainite-induced seizures, and displayed anticonvulsant and antihyperalgesic activity. Indantadol also caused a dose-dependent decrease in exploratory motility. In a human heat-capsaicin-induced pain model, indantadol at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. Indantadol undergoes extensive liver metabolism, withthe formation of two major metabolites - CHF-3567 and 2-aminoindane. The drug is excreted in urine partially as the parent compound, but mostly as CHF-3567. The tolerability profile of indantadol at single doses up to 600 mg and twice-daily doses up to 400 mg in clinical trials was significantly more favorable than for other NMDA antagonists. Most side effects have been observed to be mild, and include dizziness and asthenia. Indantadol is currently in phase II clinical trials in patients with diabetic peripheral neuropathic pain. Given the results available to date, indantadol may have a role in the treatment of neuropathic pain if the favorable pharmacokinetic profile and efficacy of the drug are maintained in more extensive clinical trials. PMID: 17786847

Particularly interesting is 2-aminoindan(e) is a metabolite.


Yohimbine

has been trialed clinically (although not sure about any regular use due to efficacy issues possibly)

MAOI properties uncertain & also possibly very low compared to other well know properties.

Thanks for pointing out that there was a contradiction on the site. Yes, yohimbine is a mild MAO inhibitor, we've corrected the file which suggested that it wasn't. MAO inhibitors are a broad category, they do not all work in the same way or have the same effects or the same intensity; even chocolate contains MAO inhibitors. In the relative scheme of things, Yohimbe is a very weak MAOI. Erowid

[Zaprenz]

Safinamide [A MAO-B in phase III so potentially on market soon]

...A third agent with MAO-B inhibition properties, safinamide, is in phase III development. Although not yet approved, safinamide may offer the added advantage of combined MAO-B and dopamine reuptake inhibition.
PMID: 18041937

[Paracelsus]

Does anybody know something about the current status of these:

Toloxatone (Humoryl) - was approved in France once. I don't know if it's still used.
Pirlindole AKA pyrazidol - I've read some things, not sure yet.
Lazabemide
Befloxatone - was in trial phase some time ago, not sure if approved.
Clorgyline?
Pargyline?